Olaya Santiago-Fernández

Olaya Santiago-Fernández

Auto-generated profile, based on publicly available information

Olaya Santiago-Fernández

Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, Bronx, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 February 2025 in Nature Aging
Verified
Journal Article
Open access
PDF file
RKRabia R. Khawaja
Rabia R. Khawaja
AMAdrián Martín-Segura
Adrián Martín-Segura
OSOlaya Santiago-Fernández
Olaya Santiago-Fernández
RSRebecca Sereda
Rebecca Sereda
KLKristen Lindenau
Kristen Lindenau
ACAna Maria Cuervo
Ana Maria Cuervo
Aging leads to progressive decline in organ and tissue integrity and function, partly due to loss of proteostasis and autophagy malfunctioning. A decrease with age in chaperone-mediated autophagy (CMA), a selective type of lysosomal degradation, has been reported in various organs and cells from rodents and humans. Disruption of CMA recapitulates features of aging, whereas activating CMA in mice protects against age-related diseases such as Alzheimer’s, retinal degeneration and/or atherosclerosis. However, sex-specific and cell-type-specific differences in CMA with aging remain unexplored. Here, using CMA reporter mice and single-cell transcriptomic data, we report that most organs and cell types show CMA decline with age, with males exhibiting a greater decline with aging. Reduced CMA is often associated with fewer lysosomes competent for CMA. Transcriptional downregulation of CMA genes may further contribute to CMA decline, especially in males. These findings suggest that CMA differences may influence organ vulnerability to age-related degeneration.

16 November 2022 in Science Advances
Verified
Journal Article
Open access
SKSusmita Kaushik
Susmita Kaushik
YJYves R. Juste
Yves R. Juste
KLKristen Lindenau
Kristen Lindenau
SDShuxian Dong
Shuxian Dong
AMAdrián Macho-González
Adrián Macho-González
ACAna Maria Cuervo
Ana Maria Cuervo
Adipogenesis is a tightly orchestrated multistep process wherein preadipocytes differentiate into adipocytes. The most studied aspect of adipogenesis is its transcriptional regulation through timely expression and silencing of a vast number of genes. However, whether turnover of key regulatory proteins per se controls adipogenesis remains largely understudied. Chaperone-mediated autophagy (CMA) is a selective form of lysosomal protein degradation that, in response to diverse cues, remodels the proteome for regulatory purposes. We report here the activation of CMA during adipocyte differentiation and show that CMA regulates adipogenesis at different steps through timely degradation of key regulatory signaling proteins and transcription factors that dictate proliferation, energetic adaptation, and signaling changes required for adipogenesis.

18 September 2022 in Aging Cell
Verified
Journal Article
Open access
GKGregory J. Krause
Gregory J. Krause
ADAntonio Diaz
Antonio Diaz
MJMaryam Jafari
Maryam Jafari
RKRabia R. Khawaja
Rabia R. Khawaja
EAEsperanza Agullo‐Pascual
Esperanza Agullo‐Pascual
ACAna Maria Cuervo
Ana Maria Cuervo
Autophagy is essential for protein quality control and regulation of the functional proteome. Failure of autophagy pathways with age contributes to loss of proteostasis in aged organisms and accelerates the progression of age‐related diseases. In this work, we show that activity of endosomal microautophagy (eMI), a selective type of autophagy occurring in late endosomes, declines with age and identify the sub‐proteome affected by this loss of function. Proteomics of late endosomes from old mice revealed an aberrant glycation signature for Hsc70, the chaperone responsible for substrate targeting to eMI. Age‐related Hsc70 glycation reduces its stability in late endosomes by favoring its organization into high molecular weight protein complexes and promoting its internalization/degradation inside late endosomes. Reduction of eMI with age associates with an increase in protein secretion, as late endosomes can release protein‐loaded exosomes upon plasma membrane fusion. Our search for molecular mediators of the eMI/secretion switch identified the exocyst‐RalA complex, known for its role in exocytosis, as a novel physiological eMI inhibitor that interacts with Hsc70 and acts directly at the late endosome membrane. This inhibitory function along with the higher exocyst‐RalA complex levels detected in late endosomes from old mice could explain, at least in part, reduced eMI activity with age. Interaction of Hsc70 with components of the exocyst‐RalA complex places this chaperone in the switch from eMI to secretion. Reduced intracellular degradation in favor of extracellular release of undegraded material with age may be relevant to the spreading of proteotoxicity associated with aging and progression of proteinopathies.

3 December 2025 in Nature Metabolism
Verified
Journal Article
Open access
PDF file
OSOlaya Santiago-Fernández
Olaya Santiago-Fernández
LCLuisa Coletto
Luisa Coletto
ITInmaculada Tasset
Inmaculada Tasset
SKSusmita Kaushik
Susmita Kaushik
ACAxel R. Concepcion
Axel R. Concepcion
ACAna Maria Cuervo
Ana Maria Cuervo
Chaperone-mediated autophagy (CMA) contributes to proteostasis maintenance by selectively degrading a subset of proteins in lysosomes. CMA declines with age in most tissues, including skeletal muscle. However, the role of CMA in skeletal muscle and the consequences of its decline remain poorly understood. Here we demonstrate that CMA regulates skeletal muscle function. We show that CMA is upregulated in skeletal muscle in response to starvation, exercise and tissue repair, but declines in ageing and obesity. Using a muscle-specific CMA-deficient mouse model, we show that CMA loss leads to progressive myopathy, including reduced muscle force and degenerative myofibre features. Comparative proteomic analyses reveal CMA-dependent changes in the mitochondrial proteome and identify the sarcoplasmic–endoplasmic reticulum Ca2+-ATPase (SERCA) as a CMA substrate. Impaired SERCA turnover in CMA-deficient skeletal muscle is associated with defective calcium (Ca2+) storage and dysregulated Ca2+ dynamics. We confirm that CMA is also downregulated with age in human skeletal muscle. Remarkably, genetic upregulation of CMA activity in old mice partially ameliorates skeletal muscle ageing phenotypes. Together, our work highlights the contribution of CMA to skeletal muscle homoeostasis and myofibre integrity.

3 December 2025 in Nature Metabolism
Verified
Journal Article
Closed access
PDF file
IRIgnacio Ramírez-Pardo
Ignacio Ramírez-Pardo
SCSilvia Campanario
Silvia Campanario
BCBhakti Chavda
Bhakti Chavda
OSOlaya Santiago-Fernández
Olaya Santiago-Fernández
MFMarta Flández
Marta Flández
PMPura Muñoz-Cánoves
Pura Muñoz-Cánoves

9 June 2025 in EMBO Molecular Medicine
Verified
Journal Article
Open access
MMMericka McCabe
Mericka McCabe
RBRajanya Bhattacharyya
Rajanya Bhattacharyya
RSRebecca Sereda
Rebecca Sereda
OSOlaya Santiago-Fernández
Olaya Santiago-Fernández
RKRabia R Khawaja
Rabia R Khawaja
EGEvripidis Gavathiotis
Evripidis Gavathiotis
Chaperone-mediated autophagy (CMA), a type of selective degradation of cytosolic proteins in lysosomes, is commonly upregulated in cancer cells, contributing to their survival and growth. The lack of a specific target for CMA inhibition has limited CMA blockage to genetic manipulations or global lysosomal function inhibition. Here, using genetic modulation, transcriptional analysis, and functional studies, we demonstrate a regulatory role for the interaction of the retinoic acid receptor alpha (RARα) and its corepressor, the nuclear receptor corepressor 1 (NCoR1), on CMA in non-small cell lung cancer (NSCLC). By targeting the disruption of the NCoR1/RARα complex with a structure-based screening strategy, we identified compound CIM7, a potent and selective CMA inhibitor that has no effect on macroautophagy. CIM7 preferentially inhibits CMA in NSCLC cells over normal cells, reduces tumor growth in NSCLC cells, and demonstrates efficacy in an in vivo xenograft mouse model with no observed toxicity in blood or major tissues. These findings reveal a druggable mechanism for selective CMA inhibition and a first-in-class CMA inhibitor as a potential therapeutic strategy for NSCLC.